2fqi: Difference between revisions

Revision as of 14:02, 28 July 2008

This article has been automatically seeded. Changes to this page should pertain to the PDB entry only and not to the protein or biomolecule in general.

File:2fqi.png

Template:STRUCTURE 2fqi

dual binding modes of a novel series of DHODH inhibitorsdual binding modes of a novel series of DHODH inhibitors

Template:ABSTRACT PUBMED 16480261

About this StructureAbout this Structure

2FQI is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

ReferenceReference

Dual binding mode of a novel series of DHODH inhibitors., Baumgartner R, Walloschek M, Kralik M, Gotschlich A, Tasler S, Mies J, Leban J, J Med Chem. 2006 Feb 23;49(4):1239-47. PMID:16480261

Page seeded by OCA on Mon Jul 28 14:02:38 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
-[[Image:2fqi.gif|left|200px]]
+{{Seed}}
+[[Image:2fqi.png|left|200px]]
 <!--
@@ Line 9: / Line 10: @@
 {{STRUCTURE_2fqi|  PDB=2fqi  |  SCENE=  }}
-'''dual binding modes of a novel series of DHODH inhibitors'''
+===dual binding modes of a novel series of DHODH inhibitors===
-==Overview==
+<!--
-Human dihydroorotate dehydrogenase (DHODH) represents an important target for the treatment of hyperproliferative and inflammatory diseases. In the cell DHODH catalyzes the rate-limiting step of the de novo pyrimidine biosynthesis. DHODH inhibition results in beneficial immunosuppressant and antiproliferative effects in diseases such as rheumatoid arthritis. Here, we present high-resolution X-ray structures of human DHODH in complex with a novel class of low molecular weight compounds that inhibit the enzyme in the nanomolar range. Some compounds showed an interesting dual binding mode within the same cocrystal strongly depending on the nature of chemical substitution. Measured in vitro activity data correlated with the prevailing mode of binding and explained the observed structure-activity relationship. Additionally, the X-ray data confirmed the competitive nature of the inhibitors toward the putative ubiquinone binding site and will guide structure-based design and synthesis of molecules with higher activity.
+The line below this paragraph, {{ABSTRACT_PUBMED_16480261}}, adds the Publication Abstract to the page
+(as it appears on PubMed at http://www.pubmed.gov), where 16480261 is the PubMed ID number.
+-->
+{{ABSTRACT_PUBMED_16480261}}
 ==About this Structure==
@@ Line 26: / Line 30: @@
 [[Category: Leban, J.]]
 [[Category: Protein inhibitor complex]]
-''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May  4 04:12:06 2008''
+''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 14:02:38 2008''